NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.2 Drugs affecting the immune response > 8.2.3 Anti-lymphocyte monoclonal antibodies > Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia - TA450

Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia - TA450

1.1Blinatumomab is recommended within its marketing authorisation as an option for treating Philadelphia-chromosome-negative relapsed or refractory precursor B-cell acute lymphoblastic leukaemia in adults, only if the company provides it with the discount agreed in the patient access scheme.

https://www.nice.org.uk/guidance/ta450

Site by Devopa
© Copyright 2019 NHS. All rights reserved.